Literature DB >> 17557695

Racial and ethnic disparities in the financial burden of prescription drugs among older Americans.

K Tom Xu1, Tyrone F Borders.   

Abstract

This study examines racial and ethnic disparities in the financial burden of prescription drugs among older Americans using a market and an egalitarian model. A nationally representative data set, the Medical Expenditure Panel Survey 2002, was used. The financial burden of prescription drugs was measured by the out-of-pocket expenditure and proportion. In the market model (utilization adjustment)., utilization was measured at the annual aggregate level by the total number of prescription drugs, the average refills and the average quantity per prescription drug. In the egalitarian model (need adjustment)., health was measured by 15 chronic and costly diseases and the SF-12. Individuals 65 years or older were included. Nationally representative estimates were calculated. Raw racial and ethnic disparities were observed in the bivariate analyses between non-Hispanic whites and Hispanics in the out-of-pocket expenditure and proportion, and between non-Hispanic whites and non-Hispanic blacks in the out-of-pocket proportion. However, these disparities disappeared after controlling for utilization or health needs. Insurance status contributed the most to the disparities in the financial burden of prescription drugs. In conclusion, The disparities in the financial burden of prescription drugs between non-Hispanic elderly whites and Hispanics may be attributable to differences in utilization patterns. However, whether health disparities contribute to disparities in the financial burden of prescription drugs requires studies of specific diseases.

Entities:  

Mesh:

Year:  2007        PMID: 17557695

Source DB:  PubMed          Journal:  J Health Hum Serv Adm        ISSN: 1079-3739


  2 in total

1.  Comparison of the Financial Burden of Survivors of Head and Neck Cancer With Other Cancer Survivors.

Authors:  Sean T Massa; Nosayaba Osazuwa-Peters; Eric Adjei Boakye; Ronald J Walker; Gregory M Ward
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2019-03-01       Impact factor: 6.223

2.  Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.

Authors:  Megan E V Caram; Mary K Oerline; Stacie Dusetzina; Lindsey A Herrel; Parth K Modi; Samuel R Kaufman; Ted A Skolarus; Brent K Hollenbeck; Vahakn Shahinian
Journal:  Cancer       Date:  2020-09-14       Impact factor: 6.860

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.